News and Announcements
OncoSil Medical Quarterly Activities & Cash Flow Report June 2016
- Published July 27, 2016 11:38AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
27th July 2016, ASX Announcement
OncoSil Medical Ltd (ASX: OSL) (Oncosil of the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 30 June 2016 (the Quarter). All financial results are in Australian dollars and are unaudited.
Highlights for the Quarter
- Filed IDE Amendment with u.S. FDA
- Further submission to the Notified Body for CE mark applicatiopn responding to all questions
- Michael Warrener, appointed Global Head of Sale and Marketing
- All 30 June 2016 options exercised for cash, with recipts of $0.9m
- Cash outflow form Operations of $2.0m for the Quarter – closing cash balance of $13.4m
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
